Randall E. Kaye
2023
In 2023, Randall E. Kaye earned a total compensation of $1.2M as Executive Vice President and Chief Medical Officer at Longboard Pharmaceuticals, a 16% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $228,690 |
|---|---|
| Option Awards | $443,113 |
| Salary | $472,500 |
| Other | $16,764 |
| Total | $1,161,067 |
Kaye received $472.5K in salary, accounting for 41% of the total pay in 2023.
Kaye also received $228.7K in non-equity incentive plan, $443.1K in option awards and $16.8K in other compensation.
Rankings
In 2023, Randall E. Kaye's compensation ranked 1,017th out of 2,785 executives tracked by ExecPay. In other words, Kaye earned more than 63.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,017 out of 2,785 | 64th |
Division Manufacturing | 609 out of 1,525 | 60th |
Major group Chemicals And Allied Products | 421 out of 864 | 51st |
Industry group Drugs | 410 out of 827 | 50th |
Industry Pharmaceutical Preparations | 278 out of 592 | 53rd |
Source: SEC filing on April 12, 2024.
Kaye's colleagues
We found two more compensation records of executives who worked with Randall E. Kaye at Longboard Pharmaceuticals in 2023.